Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.

Clin Neuropharmacol · 2018 · PMC5865491 · PMID 29432286

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

In conclusion, the use of a concomitant dopaminergic agonist or MAO-B inhibitor did not diminish the efficacy of ER CD-LD compared with IR CD-LD or CLE, whereas the improvement observed with concomitant amantadine failed to reach statistical significance.

also in 6,035 other papers

failed to reach significanceno p-value reported

Results and Conclusions Concomitant dopaminergic agonist or MAO-B inhibitor use did not diminish the efficacy (improvement in “off” time and “on” time without troublesome dyskinesia) of ER CD-LD compared with IR CD-LD or CLE, whereas the improvement with concomitant amantadine failed to reach significance.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.